Lung Fibrosis Mouse Model Selection Guide 2026
IPF preclinical model guide: Bleomycin (IT/OP/pump), Silica, FITC, aged mice, genetic models with decision framework and translational limits.
Why Model Selection Decides IPF Drug Success
In idiopathic pulmonary fibrosis (IPF), promising Phase 2 results frequently fail to translate into positive Phase 3 outcomes, and a recurring contributor is model mis-selection. Compounds that clear single-dose bleomycin often fail in the chronic, progressive human disease.
This guide compares the major lung fibrosis animal models—Bleomycin derivatives, Silica, FITC, Asbestos, aged mice, and genetic models—on a single axis so teams can choose per research goal. Pair it with Bleomycin Model Pitfalls for dosing-level detail.
Quick Answer: No single lung-fibrosis model is universal — model design should follow the research goal. Default choices by goal: (1) screening — Bleomycin IT/OP (reproducibility, low cost); (2) efficacy confirmation — Bleomycin osmotic pump + Silica (chronicity); (3) age-related mechanisms — aged mice (18–24 mo) or a genetic model as a supporting tool. ATS Jenkins 2017 key points: intervene after the acute inflammatory phase (at least Day 7–10 for bleomycin), use multiple timepoints, power for total lung hydroxyproline as the primary endpoint with Masson/Sirius Red histology as the key secondary, run initial studies in males and confirm key findings in females, and consider confirmation in a second system.
1. Model Overview (Quick Comparison)
| Model | Route | Inflammation peak | Fibrosis peak | Resolution | Translational fit | Cost |
|---|---|---|---|---|---|---|
| Bleomycin IT (intratracheal) | Single 0.75–3 U/kg | Day 0–7 | Day 14–21 | Self-resolves after Day 28[2] | △ (acute-leaning) | Low |
| Bleomycin OP (oropharyngeal aspiration) | Single (IT-equivalent) | Same as IT | Same as IT | Same as IT | △ | Low |
| Bleomycin osmotic pump (subcutaneous) | 7-day continuous[3] | Diffuse | Day 14–35 | Delayed/partial | ○ (chronic-leaning) | Medium |
| Silica (inhalation/IT)[4] | Single | Day 7–14 | Day 28–56+ persistent | None (persistent) | ○ (silicosis-leaning) | Medium–high |
| FITC[5] | Single IT | Mild | Day 14–28 | Persistent | △ | Low |
| Asbestos | Single IT | Day 7–14 | Day 28–90 | Persistent | ○ (asbestosis-leaning) | High (regulated) |
| Aged mouse (18–24 mo) | None | Spontaneous | Spontaneous (mild) | None | ○ (supports age-related mechanisms) | Very high |
| TGF-α Tg[6] | Genetic | Mild | Chronic | None | ○ | Medium–high |
| AdTGF-β1[7] | Single intratracheal | Mild | Day 14–28 | Partial | ○ | Medium |
IT = intratracheal, OP = oropharyngeal aspiration
2026 best practice: avoid single-model programs. Confirmation in a second model or system (a bleomycin derivative + Silica or aged mouse, etc.) often strengthens reviewer confidence and internal translational decision-making. ATS frames a second system as something to "consider," not a requirement.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Three Bleomycin Variants: IT vs OP vs Osmotic Pump
"Bleomycin" is not one model—IT, OP, and osmotic pump produce different diseases.
2-1. Intratracheal (IT)
- Technique: Liquid delivered via tracheotomy/intubation
- Strength: Highest reproducibility; fibrosis peaks Day 14–21
- Limitation: Acute lung injury → repair → fibrosis → partial self-resolution (Day 28–42)[2]. Poor at modeling chronic IPF.
2-2. Oropharyngeal Aspiration (OP)
- Technique: Drop suspension into pharynx under anesthesia; aspirated into lungs
- Strength: No tracheotomy needed, lower invasiveness; OP delivery produces sustained lung fibrosis[10], though a formal head-to-head OP-vs-IT comparison is limited[1]
- Limitation: Dose delivery is operator-dependent; CV 15–30% for less experienced operators
2-3. Osmotic Mini-Pump
- Technique: Subcutaneous Alzet pump for 7-day continuous delivery[3]
- Strength: Prolonged fibrosis with less self-resolution; more robust for antifibrotic evaluation
- Limitation: Higher cost/complexity; diffuse lesions require CT for assessment
Typical uses:
- Screening / early MoA → IT or OP
- Antifibrotic efficacy, resolution studies → Osmotic pump
- Continuity with prior bleomycin data → IT
3. Beyond Bleomycin: Alternative Models
3-1. Silica
Models silicosis; fibrosis persists beyond Day 28, avoiding the bleomycin resolution problem.
- Dose: Crystalline silica (2–10 mg/mouse) via inhalation or IT
- Readout: Day 28–56, mixed granuloma + fibrosis
- Limitation: Pathology diverges from IPF (occupational dust exposure)
3-2. FITC
Single-dose FITC enables fluorescence tracking of the fibrotic region[5].
- Strength: Visualizes fibrotic territories for spatial analysis
- Weakness: Disease biology overlaps bleomycin; limited novelty
3-3. Aged Mice
IPF is fundamentally age-related (onset >60 years). 18–24 months corresponds to roughly human 56–69 years, and aging may influence fibrosis susceptibility and resolution[1].
- Strength: A useful supporting model when age-related mechanisms are the question
- Weakness: Maintenance cost is very high; fibrosis is mild and needs sensitive readouts (PSR digital quant, etc.); ATS does not endorse standard/prioritized use as an efficacy model
3-4. Genetic Models
- TGF-α Tg[6]: SP-C–driven TGF-α expression → chronic fibrosis
- AdTGF-β1[7]: Adenoviral intratracheal delivery → reproducible but inflammation-heavy
4. Decision Table by Research Goal
| Goal | First choice | Second choice | Rationale |
|---|---|---|---|
| Compound screening (many arms, low cost) | Bleomycin IT/OP | — | Short, reproducible |
| Mechanism confirmation | Bleomycin IT + AdTGF-β1 | Silica | Pathological diversity |
| Antifibrotic Ph II–enabling | Bleomycin osmotic pump | Silica | Chronic, robust |
| Resolution studies | Bleomycin IT Day 21–42 | — | Leverages self-resolution |
| IPF translational evidence | Bleomycin pump + a target-dependent second system | Aged mice (for age-related targets) | Chronicity + target-appropriate validation |
| Silicosis / PM2.5 exposure | Silica | Asbestos | Particulate pathology |
| Prevention studies | TGF-α Tg | Aged mice | Long observation |
| Imaging biomarkers | Bleomycin + FITC | — | Spatial information |
5. Why Translation Fails: ATS Workshop Recommendations
Jenkins RG et al. (Am J Respir Cell Mol Biol 2017, PMID 28459387)[1] issued the ATS workshop statement on designing IPF preclinical studies:
- Dose after the acute inflammatory phase (at least Day 7–10 for bleomycin), not prevention at Day 0
- Multiple timepoints to capture time dependence
- Power for total lung hydroxyproline as the primary endpoint, with Masson or Sirius Red histology as the key secondary endpoint
- Run initial studies in males and confirm key findings in females where appropriate
- Consider confirmation in a second system (different center, model, or species) to increase confidence — not a requirement
Designs that diverge from these recommendations carry higher translational risk for Phase II/III.
Pirfenidone and Nintedanib were validated in bleomycin before Phase III success, but the pipeline of candidates that followed mostly failed—model-driven bias is a likely contributing factor.
6. Model-Specific Pitfalls
Bleomycin (common)
- Dose-dependent mortality: strain dependent; C57BL/6J sees 10–20% lethality at 3 U/kg
- Self-resolution after Day 28: inadequate for chronic endpoints
- Mixed acute injury: design timepoints that separate inflammation and fibrosis
- Strain differences: C57BL/6J vs BALB/c differ markedly[9]
Silica
- Physical properties matter: α-quartz vs cristobalite yields different severities
- Granuloma vs fibrosis: Ashcroft scoring is awkward
- Inhalation chamber standardization is hard
FITC
- Acute respiratory depression post-dosing
- Limited as a stand-alone IPF model
Aged Mice
- Cost: $500–1000+ per mouse by 18–24 months
- Dropout from natural mortality: plan group sizes accordingly
- Mild fibrosis: requires sensitive readouts (PSR digital quant, etc.)
7. Standard Endpoints
The ATS Jenkins 2017 core is total lung hydroxyproline (primary endpoint) plus whole-lobe histology (Masson/Sirius Red, key secondary endpoint)[1]. Lung function, CT, gene expression, and BALF are not routine; they are exploratory readouts added per study goal. The table below organizes the axes a program may combine:
| Axis | Endpoint examples | Role |
|---|---|---|
| Quantification (core) | Hydroxyproline[8] (right, left, or both — keep consistent within one SOP) | Primary endpoint |
| Histopathology (core) | Masson Trichrome / Sirius Red morphology, Ashcroft score | Key secondary endpoint |
| Lung function | Compliance, Resistance (FlexiVent) | Not routine; can join a composite endpoint at experienced labs |
| Molecular | Col1a1, Col3a1, Acta2 RT-qPCR | Exploratory (pair with biochemistry) |
| Cellular | BALF total cells + differential | Exploratory (to confirm pathway effects) |
See Fibrosis Quantification Comparison for Hyp/PSR methodology.
8. Summary: Goal-Driven Model Selection
There is no universal lung fibrosis model. The right combination depends on research goal, phase, budget, and regulatory expectations.
- Early screening: Bleomycin IT/OP (reproducibility, cost)
- Efficacy confirmation: Bleomycin osmotic pump + Silica (chronicity)
- Age-related mechanisms: aged mice or a genetic model as a supporting tool
- Phase III ambition: build in confirmation in a target-appropriate second system (the Jenkins 2017 approach)
Delivering the next true DMT after Pirfenidone and Nintedanib demands this multi-model rigor.
FAQ
How do I choose between Bleomycin IT, OP, and osmotic pump?
IT (intratracheal) delivers the highest reproducibility and is the default for screening and early mechanism-of-action work. OP (oropharyngeal aspiration) avoids tracheotomy and lowers invasiveness, but operator variability can push CV to 15–30%. Osmotic pump (subcutaneous) provides 7-day continuous delivery, prolongs fibrosis, and slows self-resolution — making it the preferred design for chronic, Phase II-enabling efficacy studies. Continuity with historical bleomycin data, however, generally favors IT.
Why is confirmation in a second model advisable?
ATS Jenkins 2017 recommends considering a second model or system (different center, model, or species) — not as a requirement, but because relying on bleomycin alone leaves room for model-driven bias to mask the true antifibrotic effect. Compounds that clear single-dose bleomycin frequently fail in Silica, AdTGF-β1, or chronic designs. Pairing a bleomycin derivative with Silica (or an aged mouse) strengthens reviewer confidence and internal translational decision-making.
When does an aged-mouse model make sense?
Use aged mice as a supporting tool when age-related mechanisms are the question. Human IPF typically onsets at 65–70 years; 18–24 months corresponds to roughly human 56–69 years, and aging may influence fibrosis susceptibility and resolution. ATS does not endorse aged mice for standard or prioritized efficacy use, and the trade-offs are steep: maintenance cost of $500–1000+ per mouse, natural mortality dropout, and mild fibrosis requiring sensitive readouts (PSR digital quantification). For general efficacy work, anchor on bleomycin plus a second system, adding aged mice for age-related targets.
When is the Silica model the right choice?
Choose Silica when you need fibrosis that persists beyond Day 28 — or when the target indication is silicosis or particulate-dust-exposure pathology (e.g., PM2.5). It sidesteps bleomycin's self-resolution problem and supports long antifibrotic exposure, but its mixed granuloma + fibrosis pattern makes Ashcroft scoring awkward. Silica crystalline form (α-quartz vs. cristobalite) substantially affects severity, so standardization of the dust's physical properties is critical for reproducibility.
How should I design endpoints for antifibrotic evaluation?
The ATS Jenkins 2017 core is total lung hydroxyproline (primary endpoint) plus Masson/Sirius Red whole-lobe histology (key secondary endpoint). Lung function (FlexiVent: Compliance, Resistance), CT imaging, molecular readouts (Col1a1, Col3a1, Acta2 RT-qPCR), and cellular profiling (BALF total cells and differential) are not routine — they are exploratory additions chosen per study goal. High-rigor programs extend to PSR digital quantification, scRNA-seq, and BALF cytokines. Pairing the core endpoints with exploratory readouts is what prevents single-readout bias.
Related Articles
- Bleomycin Model Pitfalls
- IPF Treatment Landscape 2025
- Fibrosis Quantification Comparison
- MASH Mouse Model Selection Guide
- Fibrosis Assessment Hub
References
1. Jenkins RG, Moore BB, Chambers RC, et al. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2017;56(5):667-679. PubMed
2. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362-382. PubMed
3. Lee R, Reese C, Bonner M, et al. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2014;306(8):L736-L748. PubMed
4. Lakatos HF, Burgess HA, Thatcher TH, et al. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse. Exp Lung Res. 2006;32(5):181-199. PubMed
5. Christensen PJ, Goodman RE, Pastoriza L, Moore B, Toews GB. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol. 1999;155(5):1773-1779. PubMed
6. Hardie WD, Le Cras TD, Jiang K, Tichelaar JW, Azhar M, Korfhagen TR. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L741-L749. PubMed
7. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997;100(4):768-776. PubMed
8. Kliment CR, Englert JM, Crum LP, Oury TD. A novel method for accurate collagen and biochemical assessment of pulmonary tissue utilizing one animal. Int J Clin Exp Pathol. 2011;4(4):349-355. PMC
9. Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1983;127(1):63-66. PubMed
10. Egger C, et al. Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. PLoS One. 2013;8(5):e63432. PubMed